News

The American Medical Association recently announced policies adopted by physician and medical student leaders from all corners of medicine on the final day of the Special Meeting of the AMA House of Delegates.

In an observational study, investigators are looking at the role of antibody secreting plasmablasts and GC B cells induced by the COVID-19 vaccines.

Ophthalmologists seek methods to control postoperative inflammation.

Exploring subtleties helps ophthalmologists understand postop surprises, drug reactions.

FDA approval of teprotumumab as therapeutic offers hope for patients.

Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.

MedShr Insights has developed an early warning system that applies natural language processing, artificial intelligence, and machine learnings.

The company’s IASAB will identify key business initiatives, ensuring they align with its strategic vision.

Investigators find little difference between the options.

Novel treatments are now shifting paradigm in care of retinal diseases.

Check out the latest cartoon!

Santen Inc. announced Thursday that the U.S. FDA has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops to treat vernal keratoconjunctivitis (VKC).

Patients who are members of racial and ethnic minority groups present clinically with worse objective measures of dry eye than patients who do not belong to these groups, new research shows.

Retinal imaging tests are providing material to train and test decision-support systems.

If approved, PDS ranibizumab would become the first and only eye implant with continuous drug delivery offering people with wet AMD.

Measurements from multiple studies show benefits of rho-kinase inhibition.

Increased access is key to preventing disease progression in patients.

According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.

Postop management with long-term topical antibiotics is critical to successful device retention.

Oyster Point Pharma announced today the enrollment of the first participant in its OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray to treat stage 1 neurotrophic keratopathy (NK).

Implandata received FDA Breakthrough Device Designation for its Eyemate-SC in April and now has CE Mark approval in the European Union.

Visible-light optical coherence tomography proves valuable in studies.

The American Medical Association is advocating equitable resource distribution of vaccinations to assist low-income countries.

According to investigators, infants may have an edge over adults, with babies demonstrating a stronger immune response to the SARS-CoV-2 virus.

Investigators find approach improved vision and visual fields in some patients.

According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.

The US Supreme Court ruled Thursday that the Affordable Care Act remains valid, rejecting a claim by several states that a recent change to the law made it unconstitutional.